Physician

Ray Morton Balyeat, MD

According to 2025 Medicare claims, Ray Balyeat, MD (NPI: 1376538769) practices ophthalmology in the Tulsa, OK market, with the plurality of this provider's patient population coming from Tulsa, OK. This provider's primary affiliated billing organization is THE EYE INSTITUTE INC (NPI: 1982638516; TIN: 731373096) and primary practice location at 74104-5641.

Balyeat's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 930 traditional Medicare patients, billed 45,221 HCPCS/CPT codes, and received $2,509,169 in Medicare payments. The top billing code was 67028 (Injection of drug into eye). Part D data shows 1,034 prescription claims across 231 beneficiaries totaling $63,138 in drug costs, led by Lumigan (Bimatoprost). Open Payments data shows 10 records totaling $385. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs did not follow a clear longitudinal pattern. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Part B Carrier Billing Trend. X-axis: year 2015-2024. Y-axis: Medicare payment, unit: USD. Field: Tot_Mdcr_Pymt_Amt. Source: Medicare Physician & Other Practitioners by Provider.0$1.3M$2.5M2015 Medicare payment: $1,622,479 (USD; Tot_Mdcr_Pymt_Amt)2016 Medicare payment: $1,805,585 (USD; Tot_Mdcr_Pymt_Amt)2017 Medicare payment: $1,865,888 (USD; Tot_Mdcr_Pymt_Amt)2018 Medicare payment: $2,089,561 (USD; Tot_Mdcr_Pymt_Amt)2019 Medicare payment: $2,165,543 (USD; Tot_Mdcr_Pymt_Amt)2020 Medicare payment: $1,892,306 (USD; Tot_Mdcr_Pymt_Amt)2021 Medicare payment: $1,942,178 (USD; Tot_Mdcr_Pymt_Amt)2022 Medicare payment: $2,187,257 (USD; Tot_Mdcr_Pymt_Amt)2023 Medicare payment: $2,243,141 (USD; Tot_Mdcr_Pymt_Amt)2024 Medicare payment: $2,509,169 (USD; Tot_Mdcr_Pymt_Amt)2015201620172018201920202021202220232024
YearPatientsClm LinesPayment
20151,15010,880$1,622,479
20161,16912,363$1,805,585
20171,33812,727$1,865,888
20181,34113,714$2,089,561
20191,30812,378$2,165,543
20201,12010,543$1,892,306
20211,08810,237$1,942,178
20221,03315,765$2,187,257
202398439,307$2,243,141
202493045,221$2,509,169

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Part D Events Trend. X-axis: year 2015-2024. Y-axis: Drug cost, unit: USD. Field: Tot_Drug_Cst. Source: Medicare Part D Prescribers by Provider.0$77K$154K2015 Drug cost: $89,885 (USD; Tot_Drug_Cst)2016 Drug cost: $88,002 (USD; Tot_Drug_Cst)2017 Drug cost: $110,008 (USD; Tot_Drug_Cst)2018 Drug cost: $128,896 (USD; Tot_Drug_Cst)2019 Drug cost: $154,357 (USD; Tot_Drug_Cst)2020 Drug cost: $147,988 (USD; Tot_Drug_Cst)2021 Drug cost: $120,536 (USD; Tot_Drug_Cst)2022 Drug cost: $117,777 (USD; Tot_Drug_Cst)2023 Drug cost: $82,279 (USD; Tot_Drug_Cst)2024 Drug cost: $63,138 (USD; Tot_Drug_Cst)2015201620172018201920202021202220232024
YearPatientsClaimsDrug Cost
20152301,194$89,885
20162571,349$88,002
20173021,516$110,008
20182741,553$128,896
20193151,628$154,357
20202791,471$147,988
20212631,253$120,536
20222621,259$117,777
2023225995$82,279
20242311,034$63,138

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

CodeDescriptionPatientsClm LinesTotal Payment
67028Injection of drug into eye3021,248$92
99214Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more325356$87
92014Established patient complete exam of visual system7611,293$85
92134Imaging of retina8041,629$28
92250Photography of the retina187216$25

Top 5 Part D drugs in 2024

By total drug costs.

DrugGenericClaimsTotal Day SupplyTotal Drug Cost
LumiganBimatoprost312,020$14,197
RhopressaNetarsudil Mesylate18880$5,404
LatanoprostLatanoprost34419,061$4,169
DifluprednateDifluprednate391,249$3,464
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol14950$3,164

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

CategoryDefinitionRecordsTotal Reported AmountTop Related Entity
General PaymentsReported payment or transfer-of-value amount.10$385Alimera Sciences, Inc.
Research PaymentsReported research-related payment or transfer-of-value amount.0$0N/R
Ownership / Investment InterestsReported value of ownership or investment interests.0$0N/R

FAQ

What Medicare data is available for Ray Morton Balyeat, MD?

Tedicare shows public-source Medicare data for Ray Morton Balyeat, MD (NPI 1376538769), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Ray Morton Balyeat, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Ray Morton Balyeat, MD?

Ray Morton Balyeat, MD is linked to THE EYE INSTITUTE INC (billing NPI 1982638516) in the available physician profile data.

Does Ray Morton Balyeat, MD have Open Payments data?

Ray Morton Balyeat, MD has 10 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.